Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
Veracyte, Inc. (VCYT) director Muna Bhanji sold 1,864 shares of Common Stock at $43.70 per share on October 19, 2026. The sale was made pursuant to a Rule 10b5-1 plan. Bhanji directly held 40,854 shares after the transaction.
Veracyte, Inc. (VCYT) director Jens Holstein reported a proposed sale of 7,500 common shares with an aggregate market value of $352,500.00 and an approximate sale date of September 24, 2026. Morgan Stanley Smith Barney LLC is listed as the broker. The notice lists the shares as acquired from the issuer through a stock option exercise, with cash payment dated September 24, 2026. It also reports that Holstein sold 5,000 common shares for an aggregate market value of $204,747.00 on September 14, 2026, during the prior three months.
VERACYTE, INC. (VCYT) reported that Global Chief Commercial Officer John Leite sold 4,015 shares of common stock on September 21, 2026 at $40.00 per share in an open-market or private transaction. After this sale, he directly holds 124,329 shares of Veracyte common stock. The sale was made pursuant to a Rule 10b5-1 trading plan adopted by Leite on June 9, 2026.
VERACYTE, INC. (VCYT) received a Form 144 notice indicating that officer John Leite plans to sell up to 4,015 shares of common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of approximately $159,776.93 and are listed on NASDAQ. The shares originate from Restricted Stock Units acquired from the issuer on September 2, 2026.
VERACYTE, INC. (VCYT) director Jens Holstein reported selling 5,000 shares of common stock on September 14, 2026 in a transaction coded as a sale in open market or private transactions. The shares were sold at a weighted average price of $40.95 per share and Holstein now holds 27,471 shares directly.
The sale was made pursuant to a Rule 10b5-1 plan adopted on June 12, 2026, and the filing states that individual sale prices during the transaction ranged from $40.57 to $41.40 per share.
VERACYTE, INC. (VCYT) director Jens Hendrik Holstein filed a Rule 144 notice indicating an intention to sell 5,000 shares of Veracyte common stock through Morgan Stanley Smith Barney LLC. The shares have an aggregate market value of $204,747 and are listed on NASDAQ. The 5,000 shares come from restricted stock awards dated June 13, 2025 (595 shares) and June 9, 2024 (4,405 shares).
Veracyte, Inc. (VCYT) completed the acquisition of Convergent Genomics Inc., a genomic diagnostics company focused on bladder cancer, under an Agreement and Plan of Merger signed on September 10, 2026. On September 14, 2026, Convergent became a wholly owned subsidiary of Veracyte through a merger with Veracyte’s Compass Merger Sub, Inc.
Veracyte paid Convergent securityholders $150 million in cash, subject to customary purchase price adjustments, and may pay up to an additional $30 million in cash upon achievement of specified UroAmp publication and reimbursement milestones. The deal brings Convergent’s UroAmp urinary tumor DNA platform into Veracyte’s portfolio, alongside Decipher Bladder and TrueMRD tests, to support bladder cancer care from urine, tissue, and blood-based diagnostics. Veracyte plans an initial UroAmp-based test aimed at guiding maintenance Bacillus Calmette-Guérin (BCG) therapy decisions, with commercialization expected in late 2028, and has incorporated Convergent’s operating expenses into its previously provided 2026 adjusted EBITDA guidance.
VERACYTE, INC. (VCYT) reported that Jonathan Wygant, its VP and Chief Accounting Officer, had 1,361 shares of common stock withheld on September 2, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units. This withholding is explicitly stated not to be a sale. After this transaction, he directly holds 43,226 shares, which include 514 shares purchased on July 31, 2026 under Veracyte’s Employee Stock Purchase Plan. No transactions are reported under a Rule 10b5-1 trading plan.
VERACYTE, INC. (VCYT) reported an insider equity event involving Global Chief Commercial Officer John Leite. On September 2, 2026, Leite had 3,961 shares of common stock withheld at $44.88 per share to satisfy tax withholding obligations tied to vesting restricted stock units.
The filing states this was a tax-withholding disposition and not an open-market sale. After this transaction, Leite directly held 128,344 shares of Veracyte common stock. No transactions were made under a Rule 10b5-1 trading plan.
VERACYTE, INC. (VCYT) reported that Chief Scientific & Med Officer Phillip G. Febbo sold common stock in planned transactions and had shares withheld for taxes. On September 4, 2026, he sold 10,405 shares at $42.8933 per share and 2,705 shares at $43.6618 per share in open-market or private transactions pursuant to a Rule 10b5-1 plan adopted on August 21, 2025. On September 2, 2026, 3,639 shares at $44.88 per share were withheld to satisfy tax withholding obligations upon vesting of restricted stock units, which the company states does not represent a sale.